AVE 2268

Drug Profile

AVE 2268

Alternative Names: AVE2268

Latest Information Update: 04 Nov 2008

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 16 Dec 2016 Biomarkers information updated
  • 31 Oct 2008 Discontinued - Phase-II for Type-2 diabetes mellitus in Europe (PO)
  • 31 Oct 2008 Discontinued - Phase-II for Type-2 diabetes mellitus in Latin America (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top